Publication: Terbinafin ve itrakonazolün onikomikoz tedavisinde uzun süreli izlem sonuçları
Abstract
Ayak tırnağı mantarı tedavisinde terbinafin ve İtrakonazolün uzun süreli İzlem sonrasındaki başarıları araştırıldı. Çalışmaya direkt mikroskopik incelemesi ve kültür sonucu pozitif olan toplam 72 hasta alındı. Bir hasta yan etki nedeniyle, 28 hasta kontrol muayenelerine gelmediği için çalışma dışı bırakıldı. Doksanaltı hafta boyunca izlenen 43 hastada, terbinafin (23 hasta), ve itrakonazol (20 hasta) tedavilerinin 48., 96. hafta sonuçları karşılaştırıldı. Tedavinin 48.haftasında terbinafin hastaların %95.6'sında, itrakonazol %65'inde başarılı bulundu (p<0.05). Doksanaltıncı haftada ise terbinafinin başarı oranı % 86.9, itrakonazol ile % 55 olarak saptandı (p<0.05). Uzun süreli İzlem sonucunda da terbinafinin itrakonazole göre üstün olan etkinliğinin devam ettiği görüldü. Ancak her iki grupta da 2. yılda nüks ve/veya reinfeksiyon sayısında artış gözlendi.
Background and design: The aim of this study was to compare the efficacy of terbinafine and itraconazole in toenail onychomycosis after a long term follow-up of two years. Materials and methods: A total of 72 patients received either terbinafine 250 mg/day for 12 weeks or itraconazole 200 mg/day for 16 weeks. Clinical symptoms and mycologic outcome were assessed in weeks 4, 8,12,16, 24, 36, 48, 96. Forty three patients who completed the study were analysed. Results: At week 48, overall success rates were 95.6% for terbinafine versus 65% for itraconazole (p<0.05). At week 96 overall success rates were 86.9 for terbinafine versus 55% for itraconazole (p<0.05). Conclusion: Terbinafine is still more effective than itraconazole in the treatment of toenail onychomycosis after two years of follow up period.
Background and design: The aim of this study was to compare the efficacy of terbinafine and itraconazole in toenail onychomycosis after a long term follow-up of two years. Materials and methods: A total of 72 patients received either terbinafine 250 mg/day for 12 weeks or itraconazole 200 mg/day for 16 weeks. Clinical symptoms and mycologic outcome were assessed in weeks 4, 8,12,16, 24, 36, 48, 96. Forty three patients who completed the study were analysed. Results: At week 48, overall success rates were 95.6% for terbinafine versus 65% for itraconazole (p<0.05). At week 96 overall success rates were 86.9 for terbinafine versus 55% for itraconazole (p<0.05). Conclusion: Terbinafine is still more effective than itraconazole in the treatment of toenail onychomycosis after two years of follow up period.